| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1179/016164103101202002 |
| P953 | full work available at URL | http://www.tandfonline.com/doi/pdf/10.1179/016164103101202002 |
| P698 | PubMed publication ID | 14503010 |
| P50 | author | Ramón Cacabelos | Q66809646 |
| P2093 | author name string | Yasuhiko Kubota | |
| Lucía Fernández-Novoa | |||
| Lola Corzo | |||
| Valter Lombardi | |||
| Victor Pichel | |||
| P2860 | cites work | Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents | Q28193259 |
| Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease | Q33920923 | ||
| Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. | Q33921362 | ||
| Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. | Q33950366 | ||
| Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses | Q34045304 | ||
| Histamine function in brain disorders | Q34407502 | ||
| Progress in the development of selective nitric oxide synthase (NOS) inhibitors. | Q34506757 | ||
| Alzheimer disease as a vascular disorder: nosological evidence | Q34589057 | ||
| Statins in the prevention and treatment of Alzheimer disease | Q34647906 | ||
| Role of nitric oxide in inflammation-mediated neurodegeneration. | Q34699707 | ||
| Pharmacogenomics in Alzheimer's disease | Q34947333 | ||
| Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death | Q34976924 | ||
| Pharmacogenomics for the treatment of dementia | Q35009345 | ||
| Vascular basis of Alzheimer's pathogenesis | Q35024982 | ||
| Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities | Q43858152 | ||
| Vascular disease and cognitive function in older men in the Caerphilly cohort | Q43897088 | ||
| The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain | Q43915384 | ||
| Serum lipoprotein levels, statin use, and cognitive function in older women | Q43915654 | ||
| Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. | Q43918834 | ||
| Neurotoxic mechanisms triggered by Alzheimer's disease-linked mutant M146L presenilin 1: involvement of NO synthase via a novel pertussis toxin target | Q43924721 | ||
| Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro | Q43962638 | ||
| Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia. | Q43972731 | ||
| Brain damage after coronary artery bypass grafting | Q44063661 | ||
| The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease | Q46155290 | ||
| Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans | Q46639824 | ||
| White matter lesions, quantitative magnetic resonance imaging, and dementia | Q48490619 | ||
| Caloric intake and the risk of Alzheimer disease | Q48520005 | ||
| Proinflammatory effects of M-CSF and A beta in hippocampal organotypic cultures | Q48627975 | ||
| Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors | Q49162079 | ||
| Prevalence of dementia and dementing diseases in Japan: the Tajiri project. | Q53249383 | ||
| Mixed dementia--the most common cause of dementia. | Q53356039 | ||
| Peripheral Blood Abnormalities in Alzheimer Disease: Evidence for Early Endothelial Dysfunction | Q62066123 | ||
| Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide | Q73289699 | ||
| Outcome at 30 days in the New England Medical Center Posterior Circulation Registry | Q77757940 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurology | Q83042 |
| Alzheimer's disease | Q11081 | ||
| pharmacogenomics | Q1152227 | ||
| P304 | page(s) | 567-580 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Neurological Research | Q15765622 |
| P1476 | title | Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications | |
| Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications | |||
| P478 | volume | 25 |
| Q40217954 | 4D flow MRI for intracranial hemodynamics assessment in Alzheimer's disease |
| Q36216389 | Alzheimer's disease--a dysfunction in cholesterol and lipid metabolism |
| Q35841709 | Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease |
| Q89200433 | Autotaxin⁻Lysophosphatidic Acid Signaling in Alzheimer's Disease |
| Q37687520 | Cardioprotection and anticholinesterases in patients with Alzheimer's disease: time for reappraisal |
| Q36492343 | Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease |
| Q34965949 | Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics |
| Q55266735 | Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. |
| Q47590149 | Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration |
| Q35976397 | Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia |
| Q37780790 | Genomics and pharmacogenomics of dementia |
| Q35852564 | Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics |
| Q36341967 | Joint analysis of structural and perfusion MRI for cognitive assessment and classification of Alzheimer's disease and normal aging |
| Q89819854 | Low-Density Lipoprotein Cholesterol and Alzheimer's Disease: A Systematic Review and Meta-Analysis |
| Q36457072 | Lysophosphatidic acid induces increased BACE1 expression and Aβ formation. |
| Q44526084 | Management of suspected Alzheimer's disease patients by specialist physicians at the first visit in Spain: First Consultation Study |
| Q45129977 | Oxidant stress and constrictor reactivity impair cerebral artery dilation in obese Zucker rats |
| Q36273420 | Pharmacogenomics and therapeutic prospects in Alzheimer's disease |
| Q37592250 | Pharmacogenomics and therapeutic strategies for dementia |
| Q35841700 | Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component |
| Q43721592 | Reciprocal induction between α-synuclein and β-amyloid in adult rat neurons |
| Q91944498 | Reflections on the Utility of the Retina as a Biomarker for Alzheimer's Disease: A Literature Review |
| Q33376859 | Risk factors for dementia in the epidemiological study of Munguialde County (Basque Country-Spain). |
| Q35050916 | Transcranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's disease |
| Q46547844 | Variability in the diagnosis and management of patients with Alzheimer's disease and cerebrovascular disease: results from the GALATEA multicentre, observational study |
Search more.